DECIPHERA PHARMACEUTICALS
Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK® is Deciphera’s switch control inhibitor for the treatment of fourth-line GIST. QINLOCK is approved in Australia, Canada, China, the European Union, Hong Kong, Switzerland, Taiwan, the United Kingdom, and the United States.
DECIPHERA PHARMACEUTICALS
Industry:
Biotechnology Health Care Medical Pharmaceutical Therapeutics
Founded:
2003-01-01
Address:
Waltham, Massachusetts, United States
Country:
United States
Website Url:
http://www.deciphera.com
Total Employee:
251+
Status:
Active
Contact:
(781) 209-6400
Email Addresses:
[email protected]
Total Funding:
886.5 M USD
Technology used in webpage:
Amazon Google Maps JsDelivr COVID-19 Amazon Virginia Region CloudFront Amazon S3 Ruby On Rails Token Microsoft OSS CDN
Similar Organizations
3Z Pharmaceuticals
3Z Pharmaceuticals focuses on developing drugs that would improve the central nervous system.
Actinium Pharmaceuticals
Actinium Pharmaceuticals develops alpha particle linked antibodies to treat cancer.
Amylyx Pharmaceuticals
Amylyx Pharmaceuticals specializes in providing solutions for Alzheimer’s and other diseases of the brain.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
AVEO Oncology
AVEO is a biopharmaceutical company that offers drug development strategies for targeted cancer therapeutics.
BioDelivery Sciences
BioDelivery Sciences is a pharmaceutical company that focuses on pain management and addiction medicine.
Elicio Therapeutics
Elicio Therapeutics develops an immuno-tumor vaccine to treat cancer.
Pacylex
Pacylex Pharmaceuticals develops a precision medicine solution for multiple common cancers.
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
STipe Therapeutics
STipe Therapeutics focuses on harnessing the innate immune system to battle cancer.
Torigen Pharmaceuticals
Torigen Pharmaceuticals focuses on providing cancer care solutions for animals.
VetSource
VetSource is a pharmaceuticals company providing pet care medication and vaccination services.
X4 Pharmaceuticals
X4 Pharmaceuticals a clinical-stage oncology company developing best-in-class oral small molecule CXCR4 antagonists for the treatment.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Viking Global Investors
Viking Global Investors investment in Series C - Deciphera Pharmaceuticals
Sphera Global Healthcare Fund
Sphera Global Healthcare Fund investment in Series C - Deciphera Pharmaceuticals
Redmile Group
Redmile Group investment in Series C - Deciphera Pharmaceuticals
New Leaf Venture Partners
New Leaf Venture Partners investment in Series C - Deciphera Pharmaceuticals
SV Health Investors
SV Health Investors investment in Series B - Deciphera Pharmaceuticals
New Leaf Venture Partners
New Leaf Venture Partners investment in Series B - Deciphera Pharmaceuticals
Official Site Inspections
http://www.deciphera.com Semrush global rank: 3.9 M Semrush visits lastest month: 3.26 K
- Host name: 23.185.0.1
- IP address: 23.185.0.1
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Deciphera Pharmaceuticals" on Search Engine
ONO Enters into a Definitive Agreement to Acquire Deciphera …
2 days ago Together, we expect to advance and accelerate each organization’s important work through combined research and development capabilities and a global commercial …See details»
Deciphera Pharmaceuticals Announces Planned 2024 Corporate …
Dec 31, 2023 WALTHAM, Mass.--(BUSINESS WIRE)--Jan. 8, 2024-- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on …See details»
Deciphera Pharmaceuticals to be Acquired by ONO …
3 days ago WALTHAM, Mass., April 29, 2024--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, …See details»
Deciphera Pharmaceuticals to be Acquired by ONO …
3 days ago Deciphera Shareholders to Receive $25.60 per Share in Cash. Deciphera’s Kinase Inhibitor Expertise and Established Commercialization Platform in Key Markets …See details»
Deciphera Pharmaceuticals to be Acquired by ONO
3 days ago Under the terms of the definitive merger agreement, ONO will acquire all outstanding shares of Deciphera for $25.60 per share in cash for a total equity value of …See details»
Deciphera Pharmaceuticals Announces Planned 2023 …
Jan 3, 2023 WALTHAM, Mass.-- ( BUSINESS WIRE )--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new …See details»
Deciphera Pharmaceuticals Provides Corporate Update …
Jan 10, 2022 Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people …See details»
Deciphera Pharmaceuticals Announces Planned 2024 Corporate …
WALTHAM, Mass., January 08, 2024--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and …See details»
Press Release Details - Deciphera Pharmaceuticals, Inc.
Feb 8, 2022 Investor Relations. Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2021 Financial Results. February 8, 2022 at 4:05 PM EST. PDF …See details»
Investors Overview | Deciphera Pharmaceuticals, Inc.
Feb 27, 2024 Investor Relations. Deciphera Pharmaceuticals (DCPH) is a biopharmaceutical company focused on discovering, developing, and delivering …See details»
Deciphera Pharmaceuticals | LinkedIn
Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer. We …See details»
2024-04-29 | NDAQ:DCPH | Press Release | Deciphera …
3 days ago The purchase price represents a premium of 74.7% to Deciphera’s closing share price of $14.65 on April 26, 2024, and a premium of 68.8% to Deciphera’s 30 …See details»
Deciphera Pharmaceuticals to be Acquired by ONO ... - BioSpace
3 days ago The Acquisition is structured as a tender offer and subsequent merger of Deciphera with a wholly-owned subsidiary of ONO. Under the terms of the definitive …See details»
Ono Pharmaceutical to acquire Deciphera Pharma for $2.4 billion …
3 days ago Ono Pharmaceutical of Japan said Monday it will acquire Deciphera Pharmaceuticals, a Boston-based maker of cancer drugs, for $2.4 billion. The all-cash …See details»
Deciphera Pharmaceuticals - Crunchbase Company Profile
Stock Symbol NASDAQ:DCPH. Company Type For Profit. Contact Email [email protected]. Phone Number (781) 209-6400. Deciphera is a …See details»
Deciphera Pharmaceuticals Announces Fourth Quarter and Full …
Dec 31, 2023 Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2023 Financial Results. February 6, 2024 at 7:00 AM EST. PDF Version. – Fourth Quarter …See details»
Deciphera Pharmaceuticals - Funding, Financials, Valuation
Funding. Deciphera Pharmaceuticals has raised a total of. $1B. in funding over 7 rounds. Their latest funding was raised on Jan 19, 2023 from a Post-IPO Equity round. …See details»
Deciphera Pharmaceuticals to be Acquired by ONO …
2 days ago Transaction Details. The Acquisition is structured as a tender offer and subsequent merger of Deciphera with a wholly-owned subsidiary of ONO. Under the …See details»
Deciphera Pharmaceuticals Announces Second Quarter 2023 …
Jun 30, 2023 WALTHAM, Mass. -- (BUSINESS WIRE)--Aug. 9, 2023-- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on …See details»
Why Is Deciphera Pharmaceuticals (DCPH) Stock Up 72% Today?
2 days ago Deciphera Pharmaceuticals stock is up on acquisition plans. The company will be acquired by ONO Pharmaceutical ( OPHLY ) for $25.60 per share in cash. That …See details»